Being Pharmacist myself, I know about this industry in detail. Its hard to say what effect this decision will have on API profits. There many drugs which are not produced by Pzifer however Pzifer does have some form of agreement with Johnson and Johnson and that could mean many non script items would also fall out of API arms. However, API owns Priceline pharmacies and many other Pharmany banner groups - so they do have other places to generate profits. Being a API share holder I am nervous about this decision - only time will tell how big of a impact it will have. Like I said if its ONLY script items then it is no big deal - if they start to include over the counter items - eg your codrals then profit will fall.
- Forums
- ASX - By Stock
- API
- hard to tell....
hard to tell....
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)